[{"id":"23f81513-7938-41a5-a700-6b3368e5b68d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00892736","created_at":"2021-04-05T16:48:27.594Z","updated_at":"2024-07-02T16:37:09.354Z","phase":"Phase 1","brief_title":"Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy","source_id_and_acronym":"NCT00892736","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA mutation • BRCA2 expression • PGR negative","tags":["HER-2 • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA mutation • BRCA2 expression • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 98","initiation":"Initiation: 04/20/2009","start_date":" 04/20/2009","primary_txt":" Primary completion: 05/19/2017","primary_completion_date":" 05/19/2017","study_txt":" Completion: 05/19/2017","study_completion_date":" 05/19/2017","last_update_posted":"2018-06-29"}]